Core Viewpoint - The company announced the final judgment of a lawsuit involving its wholly-owned subsidiary, which may have uncertain impacts on its financials due to the execution of the judgment [1][4]. Group 1: Lawsuit Background - The lawsuit originated from a dispute between the company's subsidiary, Guangzhou Baifeier Air Purification Materials Co., Ltd. (Baifeier), and Shanghai Deyou Electronic Technology Co., Ltd. regarding contracts for PTFE nano films needed for mask production [2]. - The initial claim involved a total amount of 18,441,691.80 yuan for goods and 1,386,000.00 yuan in penalties [2]. Group 2: Second Instance Judgment - The second-instance court partially upheld the appeal from Shanghai Deyou, correcting the first-instance judgment [3]. - The court ordered Shanghai Deyou to refund 11,256,957.82 yuan to Baifeier within ten days of the judgment's legal effect [3]. - The original defendant, Liu Keping, is held jointly liable for the debt [3]. Group 3: Financial Implications - The company has already made full provisions for bad debts related to the prepayments to Shanghai Deyou and for the inventory of PTFE nano films [4]. - Despite the final judgment, there remains uncertainty regarding the execution of the judgment and the potential recovery of the involved amount, which could affect the company's profits [4].

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-064 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 二、本次诉讼二审终审判决情况 广州洁特生物过滤股份有限公司 关于全资子公司诉讼事项二审判决结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任 重要内容提示： 一、本次诉讼的基本情况 广州洁特生物过滤股份有限公司（以下简称"公司"）全资子公司广州拜费尔 空气净化材料有限公司（以下简称"拜费尔"）与上海的优电子科技有限公司（以 下简称"上海的优"）分别于 2020 年 5 月 13 日和 2020 年 9 月 18 日签订了生产口 罩所需的原材料 PTFE 纳米薄膜的《购销合同》和《补充协议》，拜费尔就《购 销合同》及《补充协议》纠纷一案向广州市黄埔区人民法院（以下简称"黄埔法 院"）起诉上海的优、刘客平、李优红，诉讼涉案金额为货款 18,441,691.80 元 以及违约金 1,386,000.00 元。 2024 年 8 月，黄埔法 ...

Core Insights - Jiet Bio's stock increased by 5.45% to 19.14 CNY per share, with a trading volume of 36.47 million CNY and a turnover rate of 1.40%, resulting in a total market capitalization of 2.687 billion CNY [1] Company Overview - Guangzhou Jiet Biofilter Co., Ltd. is located in the Yonghe Economic Zone of Guangzhou, Guangdong Province, established on April 11, 2001, and listed on January 22, 2020 [1] - The company's main business involves the research, development, production, and sales of disposable plastic consumables for biological laboratories related to cell culture and liquid handling [1] - Revenue composition: Liquid handling accounts for 60.24%, cell culture for 30.74%, other supplementary products for 4.98%, and instruments and other categories for 4.04% [1] Shareholder Information - Among the top ten circulating shareholders of Jiet Bio, one fund from Huaxia Fund, Huaxia CSI 500 Index Enhanced A (007994), has entered the list, holding 1.1212 million shares, which is 0.8% of the circulating shares [2] - The estimated floating profit for this fund today is approximately 1.11 million CNY [2] - Huaxia CSI 500 Index Enhanced A was established on March 25, 2020, with a latest scale of 3.135 billion CNY, and has achieved a year-to-date return of 22.68% [2] Fund Manager Performance - The fund manager of Huaxia CSI 500 Index Enhanced A is Sun Meng, who has been in the position for 5 years and 220 days [3] - The total asset scale of the fund is 10.461 billion CNY, with the best return during the tenure being 126.46% and the worst return being 17.83% [3]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2025-063 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 可转债转股结果暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本季度转股情况：公司向不特定对象发行可转换公司债券证券"洁特转 债"自 2023 年 1 月 4 日起可转换为公司股份。自 2025 年 7 月 1 日至 2025 年 9 月 30 日期间，"洁特转债"共有人民币 54,000 元已转换为公司股票，转股数量 为 1,125 股，占"洁特转债"转股前公司已发行股份总额的 0.0008%。 ● 累计转股情况：截至 2025 年 9 月 30 日，"洁特转债"累计有人民币 57,000 元已转换为公司股票，转股数量为 1,185 股，占"洁特转债"转股前公司已发行 股份总额的 0.00084%。 ● 未转股可转债情况：截至 2025 年 9 月 30 日，"洁特转债" ...

Group 1 - The core viewpoint of the article highlights the target price increases for several listed companies, with notable gains for Dongcai Technology, Seres, and Gree Electric, showing target price increases of 51.97%, 37.62%, and 36.96% respectively [1][3] - On September 25, a total of 12 target price adjustments were made by brokerages, with the highest target price set at 32.43 yuan for Dongcai Technology [1][3] - A total of 35 listed companies received brokerage recommendations on September 25, including Sanyuan Shares, Anhui Weaving High-tech, and Yixin Pharmacy [1][3] Group 2 - On the same date, two companies had their ratings upgraded, with Renfu Pharmaceutical's rating raised from "Hold" to "Buy" by Shouchuang Securities, and Sanhuan Group's rating upgraded from "Hold" to "Buy" by Huazheng Securities [4][6] - A total of 10 companies received initial coverage from brokerages, with Frontier Biotech receiving a "Buy" rating from Kaiyuan Securities and Jiete Biotech also receiving a "Buy" rating from Xinda Securities [4][7] - Other companies receiving initial coverage include Bowei Alloy with a rating of "Hold" and Leisai Intelligent with a "Buy" rating, indicating a diverse range of sectors being covered [4][7]

Core Points - The company, JieTe Bio, announced a change in its continuous supervision sponsor representatives due to personnel changes at the sponsoring institution [2] - Guolian Minsheng Securities, which has merged with Minsheng Securities, is now responsible for the continuous supervision of JieTe Bio's 2022 convertible bond issuance project [2] - The new appointed representatives, Chen Sijie and Shang Shulei, will take over the duties from the previous representatives, Li Dongmao and Zhang Chunhui, to ensure the continuity of supervision [2]

Core Logic - The company has over 20 years of experience in the biological laboratory consumables sector, focusing on biological culture and liquid handling, with leading technical strength and a comprehensive product matrix. The company is expected to maintain rapid growth and become a global leader in laboratory consumables [1] Group 1: Overseas Market - The company is leveraging an ODM model to penetrate the global biological laboratory consumables supply chain, establishing stable partnerships with international leaders like VWR and Thermo Fisher, and exporting products to over 70 countries. The company is enhancing its brand image as "reliable quality" and "outstanding cost performance" [2] - In 2024, the company's revenue from overseas self-owned brands is expected to increase by 46.07%, with overseas revenue accounting for 18.89% of total income. This indicates a successful transition from OEM to self-owned brand, capturing more value in the international laboratory consumables supply chain [2] Group 2: Domestic Market - The company is positioned to capitalize on the opportunity for import substitution in the current international trade environment, with a strong first-mover advantage in producing disposable plastic consumables for biological laboratories. The company plans to expand its sales network by establishing 12 offices in China in 2024, enhancing service responsiveness [3] - The company is also targeting industrial clients through high-quality cell factories, serving sectors like biopharmaceuticals and vaccine production. In 2024, sales from cell factory products are projected to grow by approximately 28.55%, indicating strong growth momentum [3] Group 3: Product Development and Cost Efficiency - The company is focused on developing high-end products such as liquid culture media and cell culture bags, while optimizing its product structure. It is also improving manufacturing processes and introducing automation to steadily reduce unit manufacturing costs [4] - The establishment of an intelligent manufacturing base will support the automation upgrade of production lines and the implementation of an intelligent warehousing system, which is expected to enhance order delivery efficiency and support global business demands [4] Group 4: Financial Projections - The company forecasts revenues of 652 million yuan, 772 million yuan, and 919 million yuan for 2025-2027, with year-on-year growth rates of 16.7%, 18.3%, and 19.1% respectively. The projected net profits for the same period are 98 million yuan, 118 million yuan, and 145 million yuan, with growth rates of 35.3%, 20.6%, and 23.2% respectively [4]

| 证券代码：688026 | 证券简称：洁特生物 公告编号：2025-062 | | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | 广州洁特生物过滤股份有限公司 关于变更持续督导保荐代表人的公告 特此公告。 广州洁特生物过滤股份有限公司 2025 年 9 月 26 日 1 附：陈思捷先生、尚书磊先生简历 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）于近日收到保荐机构 国联民生证券承销保荐有限公司（以下简称"国联民生承销保荐"）《关于变更持 续督导保荐代表人的函》。 民生证券股份有限公司（以下简称"民生证券"）为公司 2022 年向不特定对 象发行可转换公司债券的保荐机构，李东茂先生和张春晖先生为公司持续督导保 荐代表人，法定持续督导期限至 2024 年 12 月 31 日。国联民生证券股份有限公 司已完成对民生证券的合并，承销保荐业务整合进入全资子公司国联民生承销保 荐，故国联民生承销保荐现为公司 2022 年度向不特定对象发行可转换公 ...

Investment Rating - The investment rating for the company is "Buy" [2] Core Views - The report highlights that the company has over 20 years of experience in the biological laboratory consumables sector, focusing on biological culture and liquid handling, with leading technical strength and a comprehensive product matrix. The company is expected to maintain rapid growth as its influence in overseas markets increases and both domestic industrial and research markets expand [3][4][5] Summary by Sections 1. Overseas Market - The company has entered the global biological laboratory consumables supply chain through an ODM model, establishing stable partnerships with international leaders like VWR and Thermo Fisher. The company has built a reputation for "reliable quality" and "outstanding cost performance," with overseas self-brand revenue increasing by 46.07% year-on-year in 2024, accounting for 18.89% of total revenue [4][14] 2. Domestic Market - The company is well-positioned to capitalize on the opportunity for import substitution in the current international trade climate. As one of the earliest producers of disposable plastic consumables in China, the company is expanding its sales network and has established 12 offices domestically in 2024. The sales of its cell factory products are expected to grow by approximately 28.55% year-on-year [5][49][53] 3. Product High-Endization and Smart Manufacturing - The company is focused on developing high-end products such as liquid culture media and cell culture bags while optimizing production processes to reduce manufacturing costs. The establishment of an intelligent manufacturing base is expected to enhance order delivery efficiency and support global business needs [6][15] 4. Financial Forecast and Investment Recommendation - The company is projected to achieve revenues of 652 million yuan, 772 million yuan, and 919 million yuan from 2025 to 2027, with year-on-year growth rates of 16.7%, 18.3%, and 19.1% respectively. The net profit attributable to the parent company is expected to be 98 million yuan, 118 million yuan, and 145 million yuan during the same period, with corresponding growth rates of 35.3%, 20.6%, and 23.2% [6][8][20]

Group 1 - The company, Guangzhou Jet Biofiltration Co., Ltd., will hold a half-year performance briefing on September 30, 2025, from 11:00 to 12:00 [2][5] - The briefing will take place at the Shanghai Stock Exchange Roadshow Center and will be conducted in an interactive online format [3][4] - Investors can submit questions for the briefing from September 23 to September 29, 2025, through the Roadshow Center website or via the company's email [6]